title: [Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine].
abstract: The effectiveness and tolerance of alizapride and metopimazine used to treat vomiting induced by acute infectious diseases were evaluated in 47 infants and children seen in five hospitals. Patients were randomized to alizapride (n = 23) or metopimazine (n = 24). Medications were given orally (drops) for 3 to 5 days. All the patients were monitored until the end of the study period. Effectiveness was excellent or good in both groups with no statistically significant difference. Clinical tolerance was outstanding in both groups; one patient in the alizapride group exhibited transient, mild drowsiness after the doses. This study confirms the good risk/benefit ratio of alizapride in the treatment of emesis in infants and children.
authors.affiliation: Service de Pédiatrie, Hôpital Saint-Joseph, Paris.
authors.forename: H
authors.initials: H
authors.lastname: Debray
authors.forename: J
authors.initials: J
authors.lastname: Guihard
authors.forename: D
authors.initials: D
authors.lastname: Peyramond
authors.forename: P
authors.initials: P
authors.lastname: Tron
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D007540:Isonipecotic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000932:Antiemetics; D007540:Isonipecotic Acids; D011759:Pyrrolidines; C005260:metopimazine; C033968:alizapride
vernacular_title: Traitement des vomissements du nourrisson et de l'enfant liés à une pathologie infectieuse aiguë. Etude comparative alizapride versus métopimazine.